Core Viewpoint - China Antibody-B (03681) has entered into a comprehensive strategic cooperation agreement with Sun Yat-sen University Hong Kong Advanced Institute of Science (SYSU-IAS) to conduct joint research and development in the biomedical field over a three-year period [1] Group 1: Strategic Cooperation - The cooperation aims to leverage the strengths of both parties to accelerate the development of innovative drugs and promote the translation of research results into clinical applications globally [1] - The collaboration will adopt a project-driven model, focusing on resource sharing and efficient communication [1] - This partnership allows the company to utilize SYSU-IAS's advanced laboratory facilities, animal supply resources (especially non-primate animals), and valuable data assets, which are crucial for driving innovation in drug research and sustainable development [1] Group 2: Long-term Growth and Sustainability - The board of directors believes that this strategic cooperation establishes a mutually beneficial framework that will help drive growth and ensure long-term sustainability [1] - The collaboration aligns with the company's strategy to advance its pipeline of innovative drug candidates [1]
中国抗体-B与中山大学香港高等研究院订立全面战略合作协议